临床药师对呼吸科感染性疾病的药学监护切入点

The pharmaceutical care entry point of clinical pharmacist for respiratory infectious diseases

目的探讨临床药师对呼吸内科感染性疾病患者实行药学监护的路径与方法。方法将我院2010年3月至2012年6月呼吸内科收治的206例住院患者的临床资料进行回顾性分析。结果药师干预组患者临床症状的消失时间明显短于非预组，差异有统计学意义（t=3．926，P〈0．05）；药师干预组总有效率（91．26％）明显高于非预组（79．61％），差异有统计学意义（X2=3．506，P〈O．05）；非预组不良反应发生率（31．07％）明显高于药师于预组（8．74％），差异有统计学意义（X2=5．306，P〈0．01）。结论临床药师参与临床用药的实践不仅可有效提高患者用药有效性、安全性，还能充分实现临床药师的自身价值。

Objective To investigate the pharmaceutical care entry point of clinical pharmacist for respiratory infectious diseases. Methods A retrospective analysis of clinical data of 206 cases of patient from March 2010 to June 2012 Respiratory in the department of respiratory. Results The clinical symptoms disappeared time of the pharmacist intervention group were significantly shorter than those of the non-intervention group （ t = 3. 926, P 〈0.05）. The total effective rate of the pharmacist intervention group were significantly higher than that of the non-intervention group （91. 26% vs 79.61%）, （X2= 3. 505, P〈0.05）. The incidence of adverse reactions of the non-intervention group were significantly higher than that of the pharmacist intervention group （31.07% vs 8.74%）, （X2 =5. 306, P 〈0.01）. Conclusions The clinical pharmacists involved in the practice of clinical medicine can not only improve patient medication efficacy and safety,hut also fully realize the value of clinical pharmacists.